证券日报网讯 1月9日，药易购在互动平台回答投资者提问时表示，投资者可参考定期报告中披露的股 东人数情况；如临时查询股东人数，可向公司提供股东持股证明以及个人身份证件等相关资料后，查询 对应信息。 （文章来源：证券日报） ...

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]

Group 1 - The stock of Shuyu Pingmin has dropped over 18% [1] - Other companies such as Renmin Tongtai, Dajia Weikang, Yingte Group, and Yao Yigou have all seen declines of over 5% [1] - Additional companies including Huaren Health, Zhongyao Holdings, and Kaikai Industrial have also experienced declines [1]

Core Viewpoint - The company, YaoYigou (300937), has successfully resolved a contractual dispute, receiving a core execution payment of 44 million yuan after a final court ruling in its favor [1] Group 1: Legal Dispute Resolution - The dispute originated in November 2022 when plaintiffs Yang Ya and Cao Jijun sued YaoYigou regarding a cooperation agreement in the Huangpu District People's Court of Guangzhou [1] - In August 2024, the first-instance court ruled to terminate the relevant agreement and ordered the defendants to jointly repay the loan of 44 million yuan to YaoYigou [1] - Both parties appealed the ruling, but in October 2025, the Guangzhou Intermediate People's Court upheld the original judgment, with the opposing party bearing most of the second-instance case acceptance fees [1] Group 2: Financial Impact - As of the announcement date, YaoYigou has received the full 44 million yuan execution payment, with an estimated late payment interest of approximately 357,400 yuan currently under court verification [1] - The company has reported 54 additional undisclosed minor lawsuits and arbitration cases in the past year, with a total amount in dispute of 21.21 million yuan, primarily related to contract disputes [1] - The received 44 million yuan will be accounted for according to accounting standards, with the final impact on the company's current or future profits to be determined by the annual audit results [1]

证券代码：300937 证券简称：药易购 公告编号：2025-051 四川合纵药易购医药股份有限公司 关于公司诉讼进展暨收到执行款项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：执行阶段； 2、公司所处的当事人地位：上诉人、原审被告、反诉原告； 3、涉案的金额：判决对方归还人民币 4,400 万元、相关费用各自承担； 4、对公司损益产生的影响：目前公司已收到对方当事人归还的人民币 4,400 万元，公司将依据案件该执行情况和有关会计准则的要求进行相应的会计处理， 最终会计处理及对公司本期利润或期后利润的影响数据将以审计机构年度审计 确认后的结果为准。敬请投资者注意投资风险。 议于 2024 年 8 月 15 日解除；2、杨亚、曹继军、享健药易购健康科技有限公司 于本判决生效之日起十日内共同向公司偿还借款 4,400 万元；3、驳回杨亚、曹 继军的其他本诉请求；4、驳回公司的其他反诉请求。"具体内容详见公司于 2024 年 8 月 19 日披露的《关于公司收到民事判决书暨诉讼进展公告》（公告编号： 2024-03 ...

（文章来源：每日经济新闻） 每经AI快讯，12月2日，医药商业板块持续拉升，海王生物5连板，人民同泰涨停，药易购、合富中 国、华人健康、益丰药房、开开实业跟涨。 ...

Group 1 - Several companies, including Shuyupingmin, Huaren Health, and Kaikai Industry, experienced a decline of over 6% [1] - Other companies such as Yaoyigou, Renmintongtai, Yingtigroup, Diyi Medical, and Yifeng Pharmacy also followed the downward trend [1]

Market Overview - The pharmaceutical commercial sector increased by 1.34% compared to the previous trading day, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Huaren Health (301408) saw a closing price of 17.40, with a significant increase of 20.00% and a trading volume of 345,500 shares, amounting to a transaction value of 570 million [1] - Other notable performers included: - Haiwang Biological (000078) with a closing price of 2.81, up 10.20% [1] - Renmin Tongtai (600829) at 13.18, up 10.02% [1] - Ruikang Pharmaceutical (002589) at 3.19, up 10.00% [1] - Yingte Group (000411) at 12.36, up 9.96% [1] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 665 million from main funds, while retail funds saw a net outflow of 366 million [2] - The main funds' net inflow for Huaren Health was 1.43 billion, representing 25.12% of the total, while retail funds had a net outflow of 596.87 million [3] - Other companies with significant main fund inflows included: - Ruikang Pharmaceutical with a net inflow of 118 million [3] - Renmin Tongtai with a net inflow of 115 million [3] - Haiwang Biological with a net inflow of 106 million [3]